ECT-Induced Seizure Length Tied to Major Depressive Disorder Remission

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on July 29, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 29, 2024 -- For patients with major depressive disorder (MDD), seizure duration of 60 to 69 seconds induced by electroconvulsive therapy (ECT) is associated with the highest remission rates compared with seizure duration of less than 20 seconds, according to a study published online July 25 in JAMA Network Open.

Cecilia Gillving, from the University Health Care Research Centre at Örebro University in Sweden, and colleagues conducted a population-based cohort study using data from the Swedish National Quality Register for ECT to examine the association between seizure duration, potential confounding variables, and ECT treatment outcome. A total of 6,998 patients with unipolar MDD treated with unilateral electrode placement were included. The analysis used electroencephalographic (EEG) seizure duration from the first ECT treatment session for each patient.

The researchers found that 39.3 percent of patients achieved remission after ECT. The highest remission rates were seen for patients with EEG seizure duration of 60 to 69 seconds compared with those with seizure duration of less than 20 seconds (odds ratio, 2.17). Associations were seen for anticonvulsant medications with shorter seizure duration and lower remission rates (e.g., lamotrigine: β coefficient, −6.02; adjusted odds ratio, 0.67).

"This cohort study is the largest yet supporting the association between seizure length and remission from MDD after ECT," the authors write. "Seizure duration appeared to be indicative of adequate treatment quality."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-30 03:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords